Should I Buy ORMP? ORMP 2026 Analysis

Should You Buy Oramed Pharmaceuticals Inc (ORMP) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.420

1 Day change

-1.44%

52 Week Range

3.710

Analysis Updated At

2026/01/26

Based on the data provided, Oramed Pharmaceuticals Inc (ORMP) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financial performance is weak, with significant declines in net income and EPS, and there are no strong positive catalysts or trading signals to support a buy decision at this time. Holding off on investment is recommended until more favorable indicators emerge.

Technical Analysis

The technical indicators for ORMP show mixed signals. While the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the MACD histogram is negative and expanding downward, suggesting bearish momentum. RSI is neutral at 47.947, and the stock is trading below the pivot level of 3.504, with key resistance at 3.657 and support at 3.352. Overall, the technical analysis does not strongly support a buy decision.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

There are no significant positive catalysts, as there is no recent news, no trading activity from insiders or hedge funds, and no recent congress trading data.

Neutral/Negative Catalysts

Additionally, the lack of recent news or significant trading activity suggests limited investor interest.

Financial Performance

In Q3 2025, the company's revenue remained at 0 with no growth, while net income dropped by 346.67% YoY to $48,395,000. EPS also declined significantly by 335.42% YoY to 1.13. Gross margin remained stable at 0.65. Overall, the financial performance is weak and does not support a buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes are available for ORMP. This lack of data limits visibility into Wall Street's view of the stock.

Analyst Rating

Wall Street analysts forecast ORMP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORMP is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy